Table 1.
Lists of clinical trials using EVs for tissue repair and regeneration
| Target tissue | Disease | Intervention | Trial purpose | Trial phase | Contry |
|---|---|---|---|---|---|
| Lung | Bronchpulmonary Dysplasia | BMMSC-EVs (UNEX-42) | NCT03857841 | Phase I | USA |
| Pneumonia by COVID-19 | MSC-CM | NCT04798716 | Phase I, Phase II | USA | |
| Acute Respiratory Distress Syndrome | ADMSC-EVs | NCT04602104 | Phase I, Phase II | China | |
| Pneumonia by COVID-19 | ADMSC-Evs | NCT04798716 | Phase I | USA | |
| Pneumonia by COVID-19 | COVID-19 Specific T cell-derived exosomes (CSTC-Exo) | NCT04389385 | Phase 1 | Turkey | |
| Bone and cartilage | Osteoarthritis | ADMSC-EVs | NCT04314661 | Phase I | Indonesia |
| Low back pain | PRP-EXSOME | NCT04849429 | Phase I | India | |
| Periodontitis | ADMSC-EVs | NCT04270006 | Early Phase 1 | Egypt | |
| Muscle | Muscular dystrophy | Cardiosphere-derived Cells-Evs(CAP-1002) | NCT03406780 | Phase 2 | USA |
| Brain | Acute ischemic stroke | MSC-EVs | NCT03384433 | Phase I, Phase II | Iran |
| Alzheimer Disease | MSC-EVs | NCT04388982 | Phase I and II | China | |
| Brain injury, Cognitive disorder | M2 macrophage-derived bioactive factors | Phase I and II | |||
| Craniofacial neuralgia | Exosome | NCT04202783 | N.A | USA | |
| Cardiovascular | Heart attack | PEP (EV-based product) | NCT04327635 | Phase I | USA |
| Aortic dissection (Multiple organ failure) | MSC-EVs | NCT04356300 | N.A | Fujian Medical University | |
| Skin | Dystrophic Epidermolysis Bullosa | MSC-EVs (AGLE 102) | NCT04173650 | Phase I/IIA | N.C |
| Skin ulcer | Plasma-derived EVs | NCT02565264 | Phase I | Japan | |
| Chronic ulcer | Stem cell-conditioned media | NCT04134676 | Phase I | Indonesia | |
| Wound healing | Platelet-EVs | NCT02565264 | Phase I | Japan | |
| Eye | Macular holes | MSC-EVs | NCT03437759 | Phase I | China |
| Dry eyes | UMSC-EVs | NCT04213248 | Phase I and II | China | |
| Pancreas | Diabetes Mellitus Type 1 | UMSC-EVs | NCT02138331 | Phase II and III | Egypt |
| Pancreatic ductal adenocarcinoma | MSC-EVs loaded KrasG12D siRNA | NCT03608631 | Phase I | USA |
Information obtained from https://clinicaltrials.gov/ on 28 April 2021
BMMSC, bone marrow-drived mesenchymal stem cells; CM, conditioned medium; ADMSC, adipose tissue-derived MSC; PRP, platelet-rich plasma; PEP, purified exosome product; UMSC, umbilical mesenchymal stem cells